PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

Pacific Biosciences (PACB) reported Q2 revenue of $39 million, split into $20 million consumables, $13 million instruments, and $6 million services, as shared by CFO Jim Gibson at the Canaccord Genuity Growth Conference. The update provides segment-level breakdown but no beat/miss or guidance change details, suggesting limited near-term market impact.

Analysis

Pacific Biosciences (PACB) reported Q2 revenue of $39 million, split into $20 million consumables, $13 million instruments, and $6 million services, as shared by CFO Jim Gibson at the Canaccord Genuity Growth Conference. The update provides segment-level breakdown but no beat/miss or guidance change details, suggesting limited near-term market impact.